SHEA and CDC ORTP Toolkits - download your copy today.
Issue link: https://eguideline.guidelinecentral.com/i/921497
12 7. e HE should ensure that the facility develops easily accessible and widely disseminated written multidisciplinary protocols for identifying, investigating, responding to, and containing facility and emerging pathogen outbreaks. 8. When HICS is activated, the HE should provide the Incident Commander (IC) with situational awareness to contribute to the common operating picture (COP) of the crisis. B.3. Role of the HE in Coordination with Stakeholders 1. When HICS is activated, the HE should assist the IC and the PIO in creating and/or reviewing messaging for internal and external stakeholders. If HICS is not activated, the HE will assist designated facility communications leadership. 2. e HE should work collaboratively with internal and external stakeholders to coordinate the outbreak response in accordance with his/her designated role within HIMT. B.4. Additional Resources and Assets for Outbreak Response 1. In coordination with the facility, the HE should know how to access and use the following resources for additional assistance: a. e facility's hazard vulnerability assessment (HVA)/risk assessment for most likely threats, in order to identify gaps b. Office of the Assistant Secretary for Preparedness and Response (ASPR) Technical Resources, Assistance Center, and Information Exchange (TRACIE) c. Internal and external stakeholders 2. e HE should have knowledge of: a. Regional centers with specialized capabilities for managing patients with suspected or confirmed infection with the pathogen of interest b. Principles and processes related to transfer of care and coordination for EMS transport B.5. Clinical and Support Activities 1. A facility, depending on its structure and resources, may engage in work on experimental vaccines, therapeutics, and/or clinical research during an emerging pathogen outbreak. If the facility determines it may have a role in these activities, it should identify external partners, resources, and HCP roles during the preparedness phase and outline them in the EOP. e HE may assume a leadership role in such activities or the facility may designate another individual to assume this role, which may involve: a. Collaboration with external partners, including HCCs or other state/territorial/regional public health authorities, industry, the US Food and Drug Administration (FDA), and facility structures such as the Human Subjects Review Committee (or equivalent), to identify experimental vaccines or therapeutics that may be used. b. Conduct of clinical research, conforming to all applicable regulations.